Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) is now available.
Hansoh Pharmaceutical Group Company Limited announced that the National Medical Products Administration has accepted the third biologics license application for XINYUE (Inebilizumab Injection) for treating generalized myasthenia gravis in adult patients. This acceptance marks a significant step in expanding the treatment options for this condition, reinforcing Hansoh’s position in the pharmaceutical industry and potentially enhancing its market share and influence in the region.
The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs. The company specializes in biologics and has a strong market presence in Chinese Mainland, Hong Kong, and Macau.
Average Trading Volume: 12,093,189
Technical Sentiment Signal: Buy
Current Market Cap: HK$154.9B
Learn more about 3692 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue